Biologic and Clinical Efficacy of LentiGlobin for Sickle.pptx
•Download as PPTX, PDF•
0 likes•20 views
Gene therapy with LentiGlobin involves genetically modifying patients' stem cells to produce HbAT87Q, an antisickling hemoglobin. A clinical trial of LentiGlobin for 24 patients with sickle cell disease showed reduced symptoms, with no patients having vaso-occlusive crises 18 months after treatment. Long-term follow up is still needed to determine if the effects of this one-time gene therapy are lifelong.
Report
Share
Report
Share
Recommended
Villamizar 2014
This document discusses gene therapy approaches for severe hemoglobin disorders like sickle cell disease and beta-thalassemia. It describes how lentiviral vectors encoding erythroid-specific expression of gamma- or beta-globin genes have been developed and tested in mouse models, showing promise in curing these diseases. Clinical trials are also emerging with positive results, though safety and efficacy must be consistently achieved before this can become a cure. Alternative strategies like reactivating endogenous gamma-globin expression or correcting beta-globin mutations are also discussed.
Hemoglobinopathy & sickle cell disease
This document summarizes research on hemoglobin disorders and sickle cell disease. It includes 13 sections on topics such as red blood cell microparticles and their effects, increased coagulation during sickle cell crises, gene therapy approaches to correcting sickling, and clinical manifestations of sickle cell disease. The summary provides an overview of key points discussed, including that a single point mutation causes sickle cell disease, hydroxyurea treatment raises fetal hemoglobin levels and decreases complications, and newer treatments are exploring anti-inflammatory and gene therapy approaches.
Sickle Cell-VOXELOTOR MODIFIED (2)Hamisi Mkindi.pptx
Sickle Cell Disease (SCD) is major health problem in
Tanzania. Every year, approximately 11000 babies are born
with SCD1, and this number is expected to double by the year
2050. Tanzania has the fourth greatest number of annual
SCD births in all of Africa, and the fifth greatest in the world.
In addition, almost 20% of the Tanzanian population carries a
copy of the sickle gene in a form of sickle cell trait (AS).
Despite these staggering statistics, Tanzania has made
progress in the fight against SCD over the past decade. In
2008, the Ministry of Health and Social Welfare by then,
recognized SCD as a priority disease in the National strategy
for Non-communicable disease 2009- 2015, calling for all
sector to cooperate in combating the disease. A chapter on
SCD was also included in the national Non-communicable
Disease Treatment Manual.
Hydroxyurea is useful in the management of individuals with SCD. It reduces the complications
of SCD in infants, children and adults based on its ability to:
o Increase haemoglobin F levels
o Increase steady state hemoglobin counts
o Lower WBC and PLTs hence moderate the chronic inflammation state in SCD
Indications for starting hydroxyurea:
All children 9 months and above with proven SCD
Adolescents and adults with the following:
o Recurrent VOC ( 3 or more severe episodes requiring admission in the last 12
months)
o Severe and/or recurrent ACS (2 or more episodes in a lifetime)
o History of stroke or abnormal TCD (≥199cm/sec)
o Severe symptomatic chronic anemia that interferes with daily activities or quality of
life
o To reduce the risk of new or recurrent stroke where chronic transfusion therapy is not
feasible.
o Recurrent priapism
o Patient with chronic kidney disease on erythropoietin to improve anemia
#SickleCell disease#Indications for Hydroxyurea#Hamisi Mkindi#CKD#Investigations:
FBP - absolute neutrophil count (ANC) > 1,500/µl, platelet > 100,000/ul, Hb> 6g/dl.
If Hb is less than 6gm/dl do Reticulocyte Count[Do not start hydroxyurea in patients with
Hgb< 6 g/dl AND absolute reticulocyte count (ARC)<100,000/µL]
Serum Creatinine - should be within normal range,
Serum ALT – should not be greater than twice the upper limit of normal,
Bilirubin Total and direct
Urine Pregnancy Test in women
HPLC - Quantification of HbF (if this test cannot be done, Hydroxyurea should be prescribed
nevertheless and an elevated baseline HbF should not affect the decision to initiate
hydroxyurea)
Case presentation
A 23-year old female presents with a rash, bruising, nosebleeds, and heavy menstruation. Her physical exam and labs reveal an isolated thrombocytopenia. Her peripheral smear shows decreased platelet numbers and slightly larger platelets, suggesting early release from the bone marrow in response to peripheral destruction. Further history and testing are needed to determine the cause of the thrombocytopenia.
Sickle cell anemia
1. The patient presented with headache and right-sided hemiplegia, consistent with an acute stroke.
2. Strokes in sickle cell disease are most commonly ischemic and occur bimodally, peaking in younger children and those over 30 years old. Hemorrhagic strokes are rarer and peak during the second decade.
3. Diagnostic workup includes blood tests and neuroimaging to determine if the stroke is ischemic or hemorrhagic, as management differs between the two.
A case presentation of Exchange Transfusion in new born infant with Neonatal ...
A case of Exchange Transfusion in new born infant with Neonatal Jaundice and Rh incompatibility
transfusion management
double volume exchange transfusion
follow up at blood centre
antibody screening
direct antiglobulin test
technique
AABB standards
reconstituted whole blood
hyperbilirubinemia
kernicterus
encephalopathy
hematocrit and volume
Hemolytic disease of the fetus and newborn
Antigens which can cross placenta
RH immunoglobulin administration
RhIg
B12 Prostate Cancer and Pernicious Anemia
This case report describes a 75-year-old man with prostate cancer undergoing watchful waiting who was found to have pernicious anemia, a severe vitamin B12 deficiency. Over 10 months, his prostate cancer progressed more rapidly than expected based on Gleason score and PSA levels. After starting vitamin B12 injections for pernicious anemia treatment, the patient's PSA and prostatic acid phosphatase levels initially increased rapidly before stabilizing. The authors propose that the patient's vitamin B12 deficiency may have modulated the growth and progression of his prostate cancer, and that B12 replacement accelerated cancer marker levels initially before stabilization. They recommend screening prostate cancer patients undergoing watchful waiting for vitamin B12 deficiency.
Abo DISCREPANCIES blood bank abo system.pptx
An ABO discrepancy occurs when forward and reverse blood grouping results do not match. This can be due to technical errors in testing or clinical issues with the patient's blood or serum. There are four main types of discrepancies caused by problems with antibody production, antigen expression, rouleaux formation, or other miscellaneous issues. Resolving the discrepancy involves carefully reviewing testing methods, repeating tests with washed red blood cells, enhancing weak reactions, or treating cells or serum to resolve underlying clinical problems indicated by the patient's history.
Recommended
Villamizar 2014
This document discusses gene therapy approaches for severe hemoglobin disorders like sickle cell disease and beta-thalassemia. It describes how lentiviral vectors encoding erythroid-specific expression of gamma- or beta-globin genes have been developed and tested in mouse models, showing promise in curing these diseases. Clinical trials are also emerging with positive results, though safety and efficacy must be consistently achieved before this can become a cure. Alternative strategies like reactivating endogenous gamma-globin expression or correcting beta-globin mutations are also discussed.
Hemoglobinopathy & sickle cell disease
This document summarizes research on hemoglobin disorders and sickle cell disease. It includes 13 sections on topics such as red blood cell microparticles and their effects, increased coagulation during sickle cell crises, gene therapy approaches to correcting sickling, and clinical manifestations of sickle cell disease. The summary provides an overview of key points discussed, including that a single point mutation causes sickle cell disease, hydroxyurea treatment raises fetal hemoglobin levels and decreases complications, and newer treatments are exploring anti-inflammatory and gene therapy approaches.
Sickle Cell-VOXELOTOR MODIFIED (2)Hamisi Mkindi.pptx
Sickle Cell Disease (SCD) is major health problem in
Tanzania. Every year, approximately 11000 babies are born
with SCD1, and this number is expected to double by the year
2050. Tanzania has the fourth greatest number of annual
SCD births in all of Africa, and the fifth greatest in the world.
In addition, almost 20% of the Tanzanian population carries a
copy of the sickle gene in a form of sickle cell trait (AS).
Despite these staggering statistics, Tanzania has made
progress in the fight against SCD over the past decade. In
2008, the Ministry of Health and Social Welfare by then,
recognized SCD as a priority disease in the National strategy
for Non-communicable disease 2009- 2015, calling for all
sector to cooperate in combating the disease. A chapter on
SCD was also included in the national Non-communicable
Disease Treatment Manual.
Hydroxyurea is useful in the management of individuals with SCD. It reduces the complications
of SCD in infants, children and adults based on its ability to:
o Increase haemoglobin F levels
o Increase steady state hemoglobin counts
o Lower WBC and PLTs hence moderate the chronic inflammation state in SCD
Indications for starting hydroxyurea:
All children 9 months and above with proven SCD
Adolescents and adults with the following:
o Recurrent VOC ( 3 or more severe episodes requiring admission in the last 12
months)
o Severe and/or recurrent ACS (2 or more episodes in a lifetime)
o History of stroke or abnormal TCD (≥199cm/sec)
o Severe symptomatic chronic anemia that interferes with daily activities or quality of
life
o To reduce the risk of new or recurrent stroke where chronic transfusion therapy is not
feasible.
o Recurrent priapism
o Patient with chronic kidney disease on erythropoietin to improve anemia
#SickleCell disease#Indications for Hydroxyurea#Hamisi Mkindi#CKD#Investigations:
FBP - absolute neutrophil count (ANC) > 1,500/µl, platelet > 100,000/ul, Hb> 6g/dl.
If Hb is less than 6gm/dl do Reticulocyte Count[Do not start hydroxyurea in patients with
Hgb< 6 g/dl AND absolute reticulocyte count (ARC)<100,000/µL]
Serum Creatinine - should be within normal range,
Serum ALT – should not be greater than twice the upper limit of normal,
Bilirubin Total and direct
Urine Pregnancy Test in women
HPLC - Quantification of HbF (if this test cannot be done, Hydroxyurea should be prescribed
nevertheless and an elevated baseline HbF should not affect the decision to initiate
hydroxyurea)
Case presentation
A 23-year old female presents with a rash, bruising, nosebleeds, and heavy menstruation. Her physical exam and labs reveal an isolated thrombocytopenia. Her peripheral smear shows decreased platelet numbers and slightly larger platelets, suggesting early release from the bone marrow in response to peripheral destruction. Further history and testing are needed to determine the cause of the thrombocytopenia.
Sickle cell anemia
1. The patient presented with headache and right-sided hemiplegia, consistent with an acute stroke.
2. Strokes in sickle cell disease are most commonly ischemic and occur bimodally, peaking in younger children and those over 30 years old. Hemorrhagic strokes are rarer and peak during the second decade.
3. Diagnostic workup includes blood tests and neuroimaging to determine if the stroke is ischemic or hemorrhagic, as management differs between the two.
A case presentation of Exchange Transfusion in new born infant with Neonatal ...
A case of Exchange Transfusion in new born infant with Neonatal Jaundice and Rh incompatibility
transfusion management
double volume exchange transfusion
follow up at blood centre
antibody screening
direct antiglobulin test
technique
AABB standards
reconstituted whole blood
hyperbilirubinemia
kernicterus
encephalopathy
hematocrit and volume
Hemolytic disease of the fetus and newborn
Antigens which can cross placenta
RH immunoglobulin administration
RhIg
B12 Prostate Cancer and Pernicious Anemia
This case report describes a 75-year-old man with prostate cancer undergoing watchful waiting who was found to have pernicious anemia, a severe vitamin B12 deficiency. Over 10 months, his prostate cancer progressed more rapidly than expected based on Gleason score and PSA levels. After starting vitamin B12 injections for pernicious anemia treatment, the patient's PSA and prostatic acid phosphatase levels initially increased rapidly before stabilizing. The authors propose that the patient's vitamin B12 deficiency may have modulated the growth and progression of his prostate cancer, and that B12 replacement accelerated cancer marker levels initially before stabilization. They recommend screening prostate cancer patients undergoing watchful waiting for vitamin B12 deficiency.
Abo DISCREPANCIES blood bank abo system.pptx
An ABO discrepancy occurs when forward and reverse blood grouping results do not match. This can be due to technical errors in testing or clinical issues with the patient's blood or serum. There are four main types of discrepancies caused by problems with antibody production, antigen expression, rouleaux formation, or other miscellaneous issues. Resolving the discrepancy involves carefully reviewing testing methods, repeating tests with washed red blood cells, enhancing weak reactions, or treating cells or serum to resolve underlying clinical problems indicated by the patient's history.
Assignment bb group c hdn
HDN is caused by maternal IgG antibodies crossing the placenta and destroying fetal red blood cells. The most common causes are Rh and ABO incompatibility. This leads to fetal anemia, jaundice, liver/spleen enlargement, hydrops fetalis, and potentially kernicterus. Management involves prevention with RhIg in Rh-negative mothers, and treatment of the fetus with intrauterine transfusions or the newborn with phototherapy or exchange transfusions. Testing of mothers and fetuses helps monitor the condition.
br-54-149.pdf
This case report describes a patient who presented with symptoms of anemia but had falsely elevated vitamin B12 levels on laboratory tests. Further investigation revealed features consistent with pernicious anemia, including the presence of intrinsic factor antibodies. The patient responded well to vitamin B12 supplementation, demonstrating that the initial vitamin B12 results were inaccurate. The report discusses how competitive binding luminescence assays used to measure vitamin B12 can produce falsely elevated results in cases of pernicious anemia due to intrinsic factor antibodies interfering with the test. It emphasizes the importance of considering additional diagnostic markers beyond vitamin B12 levels alone when pernicious anemia is suspected.
Sickle Cell Disease
The document discusses sickle cell disease, which is caused by a mutation in the hemoglobin beta gene. The mutation causes a glutamic acid to valine substitution that results in abnormal hemoglobin S. This leads red blood cells to take on a sickle shape and causes symptoms like anemia, pain crises, infections, and organ damage. The main treatment options are blood transfusions, medications, stem cell transplant, and gene therapy, as there is currently no cure for sickle cell disease.
Clonal b cells in patients with hepatitis c virus–associated mixed
Clonal b cells in patients with hepatitis c virus–associated mixedClinical Immunology Laboratory, HMRUO, Oran.
This study examined clonal B cells from patients with hepatitis C virus (HCV) associated mixed cryoglobulinemia (MC). Despite being fundamentally involved in MC pathogenesis, transcriptional profiling revealed these B cells have features of anergy and apoptosis rather than neoplastic transformation. Phenotypically, a large proportion of the patients' clonal B cells were CD21low memory B cells, which typically exhibit decreased activation and increased anergy. Functionally, the CD21low subset showed impaired calcium signaling and failed to efficiently differentiate into antibody-secreting plasmablasts, suggesting anergy. The down-regulation of activation pathways in many of the patients' expanded B cells may attenuate overstimulation from persistentSickle cell disease
This document provides an overview of sickle cell disease (SCD), including its definition, epidemiology, pathogenesis, clinical presentation, diagnosis, treatment, and counseling. SCD is caused by a genetic mutation resulting in abnormal hemoglobin called HbS. It most commonly presents as painful vasoclusive crises, acute chest syndrome, splenic sequestration, or aplastic crises. Treatment involves management of symptoms, antibiotics, hydroxyurea, blood transfusions, and counseling to enable informed family planning decisions.
Blood Transfusion Center by Slidesgo.pptx
Sickle cell trait is a genetic condition where a person inherits one normal hemoglobin gene and one sickle cell gene. People with sickle cell trait are usually healthy and asymptomatic, as they produce both normal hemoglobin and sickle hemoglobin. While blood from donors with sickle cell trait should not be transfused to patients with sickle cell disease, it is generally considered safe for them to donate blood due to their asymptomatic nature. However, under certain conditions like dehydration or low oxygen, sickle cells from donors with sickle cell trait can sickle and cause issues. New point-of-care testing allows for rapid screening of blood donors for sickle cell status.
clinical.pptx
The document describes 14 clinical cases presenting with various types of anemia. For each case, the patient's history, symptoms, lab results and differentials are provided. The cases cover different anemias including iron deficiency, aplastic, autoimmune hemolytic, thalassemia trait, chronic lymphocytic leukemia, chronic myeloid leukemia, lymphoma, liver disease-related, and thrombotic thrombocytopenic purpura. Management workup and next steps are discussed for each clinical scenario.
Hemoglobinopathies - Oct 2014
This document summarizes hemoglobin disorders like sickle cell disease and thalassemia. It describes the molecular basis of these disorders involving mutations in the genes that encode the globin chains that make up hemoglobin. Clinical manifestations like anemia, pain crises, organ damage are discussed. Treatments mentioned include antibiotics, hydration, hydroxyurea, and blood transfusions. Ongoing research explores anti-inflammatory and gene therapies to potentially cure sickle cell disease.
Sickle cell disease.ppt
Sickle cell anemia is a genetic blood disorder caused by a mutation in the beta globin gene. It results in abnormal sickle-shaped red blood cells and leads to chronic hemolytic anemia, pain crises, and organ damage. Hydroxyurea is the principle treatment and works to reduce symptoms by increasing fetal hemoglobin levels. Complications include infections, strokes, acute chest syndrome, and organ damage to tissues like the lungs, bones and eyes. Regular screening and clinical management can help prevent complications and reduce symptoms of the condition.
Abo incompatibility safiullah
This document discusses ABO incompatibility, which is a type of hemolytic disease caused by a reaction between maternal anti-A or anti-B antibodies and fetal A or B antigens. It is usually milder than Rh incompatibility. The severity of hemolysis is greater in OA incompatibility. Treatment may include phototherapy or exchange transfusion if bilirubin levels are too high.
Blood component therapy
This document provides information about blood and blood component therapy. It discusses the types of blood components that can be derived from whole blood donations, including packed red blood cells, platelet concentrates, and fresh plasma. It also outlines guidelines for choosing appropriate blood components for different patient populations and clinical situations, such as neonates, pediatric patients, and those with diseases like sickle cell anemia or thalassemia that require chronic transfusion support. Selection of blood type and volume for transfusion is discussed based on factors like the patient's symptoms, hemoglobin level, and underlying conditions.
Chronic HEP B
This document provides an overview of chronic hepatitis B, including its epidemiology, virology, pathogenesis, natural history, clinical features, diagnosis, treatment, and guidelines. Some key points:
- Approximately 1/3 of the world's population has been infected with hepatitis B virus (HBV) and 350-400 million people are chronic carriers.
- HBV is classified into 8 genotypes that vary in prevalence around the world. HBV infects liver cells and can establish a lifelong infection by integrating into the host genome.
- Chronic HBV progresses through 5 phases and can lead to complications like cirrhosis and liver cancer if left untreated. Treatment aims to suppress HBV DNA levels and improve liver health. First
Gal-9 Sigma Xi ppt
Galectin-9 helps regulate human B cell adhesion to and migration through human vascular endothelium. Galectin-9 is expressed on high endothelial venules and circulating B cells express ligands that bind galectin-9. Galectin-9 promotes B cell adhesion to endothelial cells while reducing trans-endothelial migration. The mechanism involves galectin-9 increasing the expression of SLAMF7 on B cells while decreasing the expression of EAT-2, resulting in altered B cell signaling and migration.
Akram et al-2018-journal_of_viral_hepatitis
Detection of Hepatitis B Virus DNA among Chronic and potential Occult HBV patients in resource‐limited settings by Loop‐Mediated Isothermal Amplification assay
Heme conf 10 08-2015 - dr cho
This patient case involves a 56-year-old man with a history of JAK2 V617F+ essential thrombocythemia who developed severe anemia and was found to have myelodysplastic syndrome/myelofibrosis. He presented with transfusion-dependent anemia and was found to have concurrent warm autoantibody-mediated hemolytic anemia and delayed hemolytic transfusion reaction due to alloimmunization to the Kell blood group antigen. He required intensive care for management of his conditions.
Verhovsek_et_al-2012-Pediatric_Blood_&_Cancer
This document reports on a case of severe fetal and neonatal hemolytic anemia caused by a 198 kb deletion removing the entire b-globin gene cluster. The proband had life-threatening anemia in utero and as a newborn that required multiple transfusions. By one year of age, the severe hemolysis had subsided and the patient was left with a stable microcytic hypochromic anemia. Molecular testing identified the deletion, which removed the b-globin locus control region and all downstream b-like globin genes. This deletion had previously been seen in members of the patient's family of Irish/Scottish descent.
Clinical Case Study
The patient is a 71-year-old female who presented to the emergency room with shortness of breath, feeling faint, and dizziness. She has a history of diabetes, hypertension, chronic kidney disease, and myelodysplastic syndrome. Laboratory tests showed low red blood cell counts and hemoglobin due to bone marrow failure from her myelodysplastic syndrome. She was given two units of red blood cells due to her anemia. Her diagnoses is symptomatic anemia from her myelodysplastic syndrome, which carries a poor prognosis including a high risk of developing leukemia.
Granulocyte antigens & antibodies and their role in transfusion medicinepptx
what are granulocytes?
Granulocyte antigens
neonatal alloimmune neutropenia (NAN)
Transfusion-related acute lung injury (TRALI)
immune neutropenia after HPC transplantation
refractoriness to granulocyte transfusion
chronic benign autoimmune neutropenia of infancy (AIN)
Antigens on FcyRIIIb (CD16b)
Antigens on CD177
Antigens on CTL2
Antigens on CD11a and CD11b
Immune neutrophil disorders
granulocyte agglutination tests
GRANULOCYTE IMMUNOFLUORESCENCE test
HNA typing
Monoclonal-antibody capture assays:
RBC TF.pptx
Red Blood cell transfusion in paediatrics. How and when to transfuse anaemic patients in paediatrics. Looking at specific conditions.
blood bank seminar
Hemolytic Disease of the Newborn (HDN) is caused by maternal antibodies destroying fetal red blood cells. The most common cause is Rh disease, where an Rh-negative mother produces antibodies against Rh+ antigens from the father. These antibodies cross the placenta and cause anemia or hydrops fetalis in the fetus or newborn. Diagnosis involves serological testing of the mother's blood type and antibody screen during pregnancy. Management may include Rh immunoglobulin injections for the mother or intrauterine transfusions for severe cases of fetal anemia.
bordetella pertussis.................................ppt
Bordettela is a gram negative cocobacilli spread by air born drop let
原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样
原版纸张【微信：741003700 】【(carleton毕业证书)卡尔顿大学毕业证】【微信：741003700 】学位证，留信认证（真实可查，永久存档）offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原海外各大学 Bachelor Diploma degree, Master Degree Diploma
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
More Related Content
Similar to Biologic and Clinical Efficacy of LentiGlobin for Sickle.pptx
Assignment bb group c hdn
HDN is caused by maternal IgG antibodies crossing the placenta and destroying fetal red blood cells. The most common causes are Rh and ABO incompatibility. This leads to fetal anemia, jaundice, liver/spleen enlargement, hydrops fetalis, and potentially kernicterus. Management involves prevention with RhIg in Rh-negative mothers, and treatment of the fetus with intrauterine transfusions or the newborn with phototherapy or exchange transfusions. Testing of mothers and fetuses helps monitor the condition.
br-54-149.pdf
This case report describes a patient who presented with symptoms of anemia but had falsely elevated vitamin B12 levels on laboratory tests. Further investigation revealed features consistent with pernicious anemia, including the presence of intrinsic factor antibodies. The patient responded well to vitamin B12 supplementation, demonstrating that the initial vitamin B12 results were inaccurate. The report discusses how competitive binding luminescence assays used to measure vitamin B12 can produce falsely elevated results in cases of pernicious anemia due to intrinsic factor antibodies interfering with the test. It emphasizes the importance of considering additional diagnostic markers beyond vitamin B12 levels alone when pernicious anemia is suspected.
Sickle Cell Disease
The document discusses sickle cell disease, which is caused by a mutation in the hemoglobin beta gene. The mutation causes a glutamic acid to valine substitution that results in abnormal hemoglobin S. This leads red blood cells to take on a sickle shape and causes symptoms like anemia, pain crises, infections, and organ damage. The main treatment options are blood transfusions, medications, stem cell transplant, and gene therapy, as there is currently no cure for sickle cell disease.
Clonal b cells in patients with hepatitis c virus–associated mixed
Clonal b cells in patients with hepatitis c virus–associated mixedClinical Immunology Laboratory, HMRUO, Oran.
This study examined clonal B cells from patients with hepatitis C virus (HCV) associated mixed cryoglobulinemia (MC). Despite being fundamentally involved in MC pathogenesis, transcriptional profiling revealed these B cells have features of anergy and apoptosis rather than neoplastic transformation. Phenotypically, a large proportion of the patients' clonal B cells were CD21low memory B cells, which typically exhibit decreased activation and increased anergy. Functionally, the CD21low subset showed impaired calcium signaling and failed to efficiently differentiate into antibody-secreting plasmablasts, suggesting anergy. The down-regulation of activation pathways in many of the patients' expanded B cells may attenuate overstimulation from persistentSickle cell disease
This document provides an overview of sickle cell disease (SCD), including its definition, epidemiology, pathogenesis, clinical presentation, diagnosis, treatment, and counseling. SCD is caused by a genetic mutation resulting in abnormal hemoglobin called HbS. It most commonly presents as painful vasoclusive crises, acute chest syndrome, splenic sequestration, or aplastic crises. Treatment involves management of symptoms, antibiotics, hydroxyurea, blood transfusions, and counseling to enable informed family planning decisions.
Blood Transfusion Center by Slidesgo.pptx
Sickle cell trait is a genetic condition where a person inherits one normal hemoglobin gene and one sickle cell gene. People with sickle cell trait are usually healthy and asymptomatic, as they produce both normal hemoglobin and sickle hemoglobin. While blood from donors with sickle cell trait should not be transfused to patients with sickle cell disease, it is generally considered safe for them to donate blood due to their asymptomatic nature. However, under certain conditions like dehydration or low oxygen, sickle cells from donors with sickle cell trait can sickle and cause issues. New point-of-care testing allows for rapid screening of blood donors for sickle cell status.
clinical.pptx
The document describes 14 clinical cases presenting with various types of anemia. For each case, the patient's history, symptoms, lab results and differentials are provided. The cases cover different anemias including iron deficiency, aplastic, autoimmune hemolytic, thalassemia trait, chronic lymphocytic leukemia, chronic myeloid leukemia, lymphoma, liver disease-related, and thrombotic thrombocytopenic purpura. Management workup and next steps are discussed for each clinical scenario.
Hemoglobinopathies - Oct 2014
This document summarizes hemoglobin disorders like sickle cell disease and thalassemia. It describes the molecular basis of these disorders involving mutations in the genes that encode the globin chains that make up hemoglobin. Clinical manifestations like anemia, pain crises, organ damage are discussed. Treatments mentioned include antibiotics, hydration, hydroxyurea, and blood transfusions. Ongoing research explores anti-inflammatory and gene therapies to potentially cure sickle cell disease.
Sickle cell disease.ppt
Sickle cell anemia is a genetic blood disorder caused by a mutation in the beta globin gene. It results in abnormal sickle-shaped red blood cells and leads to chronic hemolytic anemia, pain crises, and organ damage. Hydroxyurea is the principle treatment and works to reduce symptoms by increasing fetal hemoglobin levels. Complications include infections, strokes, acute chest syndrome, and organ damage to tissues like the lungs, bones and eyes. Regular screening and clinical management can help prevent complications and reduce symptoms of the condition.
Abo incompatibility safiullah
This document discusses ABO incompatibility, which is a type of hemolytic disease caused by a reaction between maternal anti-A or anti-B antibodies and fetal A or B antigens. It is usually milder than Rh incompatibility. The severity of hemolysis is greater in OA incompatibility. Treatment may include phototherapy or exchange transfusion if bilirubin levels are too high.
Blood component therapy
This document provides information about blood and blood component therapy. It discusses the types of blood components that can be derived from whole blood donations, including packed red blood cells, platelet concentrates, and fresh plasma. It also outlines guidelines for choosing appropriate blood components for different patient populations and clinical situations, such as neonates, pediatric patients, and those with diseases like sickle cell anemia or thalassemia that require chronic transfusion support. Selection of blood type and volume for transfusion is discussed based on factors like the patient's symptoms, hemoglobin level, and underlying conditions.
Chronic HEP B
This document provides an overview of chronic hepatitis B, including its epidemiology, virology, pathogenesis, natural history, clinical features, diagnosis, treatment, and guidelines. Some key points:
- Approximately 1/3 of the world's population has been infected with hepatitis B virus (HBV) and 350-400 million people are chronic carriers.
- HBV is classified into 8 genotypes that vary in prevalence around the world. HBV infects liver cells and can establish a lifelong infection by integrating into the host genome.
- Chronic HBV progresses through 5 phases and can lead to complications like cirrhosis and liver cancer if left untreated. Treatment aims to suppress HBV DNA levels and improve liver health. First
Gal-9 Sigma Xi ppt
Galectin-9 helps regulate human B cell adhesion to and migration through human vascular endothelium. Galectin-9 is expressed on high endothelial venules and circulating B cells express ligands that bind galectin-9. Galectin-9 promotes B cell adhesion to endothelial cells while reducing trans-endothelial migration. The mechanism involves galectin-9 increasing the expression of SLAMF7 on B cells while decreasing the expression of EAT-2, resulting in altered B cell signaling and migration.
Akram et al-2018-journal_of_viral_hepatitis
Detection of Hepatitis B Virus DNA among Chronic and potential Occult HBV patients in resource‐limited settings by Loop‐Mediated Isothermal Amplification assay
Heme conf 10 08-2015 - dr cho
This patient case involves a 56-year-old man with a history of JAK2 V617F+ essential thrombocythemia who developed severe anemia and was found to have myelodysplastic syndrome/myelofibrosis. He presented with transfusion-dependent anemia and was found to have concurrent warm autoantibody-mediated hemolytic anemia and delayed hemolytic transfusion reaction due to alloimmunization to the Kell blood group antigen. He required intensive care for management of his conditions.
Verhovsek_et_al-2012-Pediatric_Blood_&_Cancer
This document reports on a case of severe fetal and neonatal hemolytic anemia caused by a 198 kb deletion removing the entire b-globin gene cluster. The proband had life-threatening anemia in utero and as a newborn that required multiple transfusions. By one year of age, the severe hemolysis had subsided and the patient was left with a stable microcytic hypochromic anemia. Molecular testing identified the deletion, which removed the b-globin locus control region and all downstream b-like globin genes. This deletion had previously been seen in members of the patient's family of Irish/Scottish descent.
Clinical Case Study
The patient is a 71-year-old female who presented to the emergency room with shortness of breath, feeling faint, and dizziness. She has a history of diabetes, hypertension, chronic kidney disease, and myelodysplastic syndrome. Laboratory tests showed low red blood cell counts and hemoglobin due to bone marrow failure from her myelodysplastic syndrome. She was given two units of red blood cells due to her anemia. Her diagnoses is symptomatic anemia from her myelodysplastic syndrome, which carries a poor prognosis including a high risk of developing leukemia.
Granulocyte antigens & antibodies and their role in transfusion medicinepptx
what are granulocytes?
Granulocyte antigens
neonatal alloimmune neutropenia (NAN)
Transfusion-related acute lung injury (TRALI)
immune neutropenia after HPC transplantation
refractoriness to granulocyte transfusion
chronic benign autoimmune neutropenia of infancy (AIN)
Antigens on FcyRIIIb (CD16b)
Antigens on CD177
Antigens on CTL2
Antigens on CD11a and CD11b
Immune neutrophil disorders
granulocyte agglutination tests
GRANULOCYTE IMMUNOFLUORESCENCE test
HNA typing
Monoclonal-antibody capture assays:
RBC TF.pptx
Red Blood cell transfusion in paediatrics. How and when to transfuse anaemic patients in paediatrics. Looking at specific conditions.
blood bank seminar
Hemolytic Disease of the Newborn (HDN) is caused by maternal antibodies destroying fetal red blood cells. The most common cause is Rh disease, where an Rh-negative mother produces antibodies against Rh+ antigens from the father. These antibodies cross the placenta and cause anemia or hydrops fetalis in the fetus or newborn. Diagnosis involves serological testing of the mother's blood type and antibody screen during pregnancy. Management may include Rh immunoglobulin injections for the mother or intrauterine transfusions for severe cases of fetal anemia.
Similar to Biologic and Clinical Efficacy of LentiGlobin for Sickle.pptx (20)
Clonal b cells in patients with hepatitis c virus–associated mixed
Clonal b cells in patients with hepatitis c virus–associated mixed
Granulocyte antigens & antibodies and their role in transfusion medicinepptx
Granulocyte antigens & antibodies and their role in transfusion medicinepptx
Recently uploaded
bordetella pertussis.................................ppt
Bordettela is a gram negative cocobacilli spread by air born drop let
原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样
原版纸张【微信：741003700 】【(carleton毕业证书)卡尔顿大学毕业证】【微信：741003700 】学位证，留信认证（真实可查，永久存档）offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原海外各大学 Bachelor Diploma degree, Master Degree Diploma
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
8.Isolation of pure cultures and preservation of cultures.pdf
Isolation of pure culture, its various method.
在线办理(salfor毕业证书)索尔福德大学毕业证毕业完成信一模一样
学校原件一模一样【微信：741003700 】《(salfor毕业证书)索尔福德大学毕业证》【微信：741003700 】学位证，留信认证（真实可查，永久存档）原件一模一样纸张工艺/offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原。
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
【主营项目】
一.毕业证【q微741003700】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
如果您处于以下几种情况：
◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【q/微741003700】
◇面对父母的压力，希望尽快拿到；
◇不清楚认证流程以及材料该如何准备；
◇回国时间很长，忘记办理；
◇回国马上就要找工作，办给用人单位看；
◇企事业单位必须要求办理的
◇需要报考公务员、购买免税车、落转户口
◇申请留学生创业基金
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
Compexometric titration/Chelatorphy titration/chelating titration
Classification
Metal ion ion indicators
Masking and demasking reagents
Estimation of Magnisium sulphate
Calcium gluconate
Complexometric Titration/ chelatometry titration/chelating titration, introduction, Types-
1.Direct Titration
2.Back Titration
3.Replacement Titration
4.Indirect Titration
Masking agent, Demasking agents
formation of complex
comparition between masking and demasking agents,
Indicators/Metal ion indicators/ Metallochromic indicators/pM indicators,
Visual Technique,PM indicators (metallochromic), Indicators of pH, Redox Indicators
Instrumental Techniques-Photometry
Potentiometry
Miscellaneous methods.
Complex titration with EDTA.
Unlocking the mysteries of reproduction: Exploring fecundity and gonadosomati...
The pygmy halfbeak Dermogenys colletei, is known for its viviparous nature, this presents an intriguing case of relatively low fecundity, raising questions about potential compensatory reproductive strategies employed by this species. Our study delves into the examination of fecundity and the Gonadosomatic Index (GSI) in the Pygmy Halfbeak, D. colletei (Meisner, 2001), an intriguing viviparous fish indigenous to Sarawak, Borneo. We hypothesize that the Pygmy halfbeak, D. colletei, may exhibit unique reproductive adaptations to offset its low fecundity, thus enhancing its survival and fitness. To address this, we conducted a comprehensive study utilizing 28 mature female specimens of D. colletei, carefully measuring fecundity and GSI to shed light on the reproductive adaptations of this species. Our findings reveal that D. colletei indeed exhibits low fecundity, with a mean of 16.76 ± 2.01, and a mean GSI of 12.83 ± 1.27, providing crucial insights into the reproductive mechanisms at play in this species. These results underscore the existence of unique reproductive strategies in D. colletei, enabling its adaptation and persistence in Borneo's diverse aquatic ecosystems, and call for further ecological research to elucidate these mechanisms. This study lends to a better understanding of viviparous fish in Borneo and contributes to the broader field of aquatic ecology, enhancing our knowledge of species adaptations to unique ecological challenges.
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...Abdul Wali Khan University Mardan,kP,Pakistan
hematic appreciation test is a psychological assessment tool used to measure an individual's appreciation and understanding of specific themes or topics. This test helps to evaluate an individual's ability to connect different ideas and concepts within a given theme, as well as their overall comprehension and interpretation skills. The results of the test can provide valuable insights into an individual's cognitive abilities, creativity, and critical thinking skillsImmersive Learning That Works: Research Grounding and Paths Forward
We will metaverse into the essence of immersive learning, into its three dimensions and conceptual models. This approach encompasses elements from teaching methodologies to social involvement, through organizational concerns and technologies. Challenging the perception of learning as knowledge transfer, we introduce a 'Uses, Practices & Strategies' model operationalized by the 'Immersive Learning Brain' and ‘Immersion Cube’ frameworks. This approach offers a comprehensive guide through the intricacies of immersive educational experiences and spotlighting research frontiers, along the immersion dimensions of system, narrative, and agency. Our discourse extends to stakeholders beyond the academic sphere, addressing the interests of technologists, instructional designers, and policymakers. We span various contexts, from formal education to organizational transformation to the new horizon of an AI-pervasive society. This keynote aims to unite the iLRN community in a collaborative journey towards a future where immersive learning research and practice coalesce, paving the way for innovative educational research and practice landscapes.
Authoring a personal GPT for your research and practice: How we created the Q...
Thematic analysis in qualitative research is a time-consuming and systematic task, typically done using teams. Team members must ground their activities on common understandings of the major concepts underlying the thematic analysis, and define criteria for its development. However, conceptual misunderstandings, equivocations, and lack of adherence to criteria are challenges to the quality and speed of this process. Given the distributed and uncertain nature of this process, we wondered if the tasks in thematic analysis could be supported by readily available artificial intelligence chatbots. Our early efforts point to potential benefits: not just saving time in the coding process but better adherence to criteria and grounding, by increasing triangulation between humans and artificial intelligence. This tutorial will provide a description and demonstration of the process we followed, as two academic researchers, to develop a custom ChatGPT to assist with qualitative coding in the thematic data analysis process of immersive learning accounts in a survey of the academic literature: QUAL-E Immersive Learning Thematic Analysis Helper. In the hands-on time, participants will try out QUAL-E and develop their ideas for their own qualitative coding ChatGPT. Participants that have the paid ChatGPT Plus subscription can create a draft of their assistants. The organizers will provide course materials and slide deck that participants will be able to utilize to continue development of their custom GPT. The paid subscription to ChatGPT Plus is not required to participate in this workshop, just for trying out personal GPTs during it.
Micronuclei test.M.sc.zoology.fisheries.
Current Ms word generated power point presentation covers major details about the micronuclei test. It's significance and assays to conduct it. It is used to detect the micronuclei formation inside the cells of nearly every multicellular organism. It's formation takes place during chromosomal sepration at metaphase.
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...University of Maribor
Slides from talk:
Aleš Zamuda: Remote Sensing and Computational, Evolutionary, Supercomputing, and Intelligent Systems.
11th International Conference on Electrical, Electronics and Computer Engineering (IcETRAN), Niš, 3-6 June 2024
Inter-Society Networking Panel GRSS/MTT-S/CIS Panel Session: Promoting Connection and Cooperation
https://www.etran.rs/2024/en/home-english/Thornton ESPP slides UK WW Network 4_6_24.pdf
ESPP presentation to EU Waste Water Network, 4th June 2024 “EU policies driving nutrient removal and recycling
and the revised UWWTD (Urban Waste Water Treatment Directive)”
Shallowest Oil Discovery of Turkiye.pptx
The Petroleum System of the Çukurova Field - the Shallowest Oil Discovery of Türkiye, Adana
Describing and Interpreting an Immersive Learning Case with the Immersion Cub...
Current descriptions of immersive learning cases are often difficult or impossible to compare. This is due to a myriad of different options on what details to include, which aspects are relevant, and on the descriptive approaches employed. Also, these aspects often combine very specific details with more general guidelines or indicate intents and rationales without clarifying their implementation. In this paper we provide a method to describe immersive learning cases that is structured to enable comparisons, yet flexible enough to allow researchers and practitioners to decide which aspects to include. This method leverages a taxonomy that classifies educational aspects at three levels (uses, practices, and strategies) and then utilizes two frameworks, the Immersive Learning Brain and the Immersion Cube, to enable a structured description and interpretation of immersive learning cases. The method is then demonstrated on a published immersive learning case on training for wind turbine maintenance using virtual reality. Applying the method results in a structured artifact, the Immersive Learning Case Sheet, that tags the case with its proximal uses, practices, and strategies, and refines the free text case description to ensure that matching details are included. This contribution is thus a case description method in support of future comparative research of immersive learning cases. We then discuss how the resulting description and interpretation can be leveraged to change immersion learning cases, by enriching them (considering low-effort changes or additions) or innovating (exploring more challenging avenues of transformation). The method holds significant promise to support better-grounded research in immersive learning.
The debris of the ‘last major merger’ is dynamically young
The Milky Way’s (MW) inner stellar halo contains an [Fe/H]-rich component with highly eccentric orbits, often referred to as the
‘last major merger.’ Hypotheses for the origin of this component include Gaia-Sausage/Enceladus (GSE), where the progenitor
collided with the MW proto-disc 8–11 Gyr ago, and the Virgo Radial Merger (VRM), where the progenitor collided with the
MW disc within the last 3 Gyr. These two scenarios make different predictions about observable structure in local phase space,
because the morphology of debris depends on how long it has had to phase mix. The recently identified phase-space folds in Gaia
DR3 have positive caustic velocities, making them fundamentally different than the phase-mixed chevrons found in simulations
at late times. Roughly 20 per cent of the stars in the prograde local stellar halo are associated with the observed caustics. Based
on a simple phase-mixing model, the observed number of caustics are consistent with a merger that occurred 1–2 Gyr ago.
We also compare the observed phase-space distribution to FIRE-2 Latte simulations of GSE-like mergers, using a quantitative
measurement of phase mixing (2D causticality). The observed local phase-space distribution best matches the simulated data
1–2 Gyr after collision, and certainly not later than 3 Gyr. This is further evidence that the progenitor of the ‘last major merger’
did not collide with the MW proto-disc at early times, as is thought for the GSE, but instead collided with the MW disc within
the last few Gyr, consistent with the body of work surrounding the VRM.
Recently uploaded (20)
bordetella pertussis.................................ppt
bordetella pertussis.................................ppt
8.Isolation of pure cultures and preservation of cultures.pdf
8.Isolation of pure cultures and preservation of cultures.pdf
Compexometric titration/Chelatorphy titration/chelating titration
Compexometric titration/Chelatorphy titration/chelating titration
Unlocking the mysteries of reproduction: Exploring fecundity and gonadosomati...
Unlocking the mysteries of reproduction: Exploring fecundity and gonadosomati...
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
Immersive Learning That Works: Research Grounding and Paths Forward
Immersive Learning That Works: Research Grounding and Paths Forward
Authoring a personal GPT for your research and practice: How we created the Q...
Authoring a personal GPT for your research and practice: How we created the Q...
Basics of crystallography, crystal systems, classes and different forms
Basics of crystallography, crystal systems, classes and different forms
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
Describing and Interpreting an Immersive Learning Case with the Immersion Cub...
Describing and Interpreting an Immersive Learning Case with the Immersion Cub...
The debris of the ‘last major merger’ is dynamically young
The debris of the ‘last major merger’ is dynamically young
Biologic and Clinical Efficacy of LentiGlobin for Sickle.pptx
- 1. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease Journal Article on Recent Advances in Genetics
- 2. BEST FOR You O R G A N I C S C O M P A N Y Background Sickle cell disease is characterized by the painful recurrence of vaso- occlusive events. Gene therapy with the use of LentiGlobin for sickle cell disease (bb1111:lovotibeglolene autotemcel)consist of autologous transplantation of hematopoietic stem and progenitor cells transduced with the BB305 lentiviral vector encoding a modified B-globin gene, which produces an antisickling hemoglobin, HbAT87Q 2
- 3. BEST FOR You O R G A N I C S C O M P A N Y 3 Sickle Cell Single point mutation in the gene encoding B-globin (HBB) Patients with sickle cell disease may suffer Vas0-occlusive events Progressive vasculopathy Chronic Hemolytic Anemia
- 4. BEST FOR You O R G A N I C S C O M P A N Y 4 Treatment for Sickle Cell Anemia HLA-matched sibling allogenic hematopoietic treatment
- 5. BEST FOR You O R G A N I C S C O M P A N Y 5 LENTIGLOBIN A gene therapy consist of the autologous transplantation of hematopoietic stem and progenitor cells (HSPCs) transduced with the BB305 lentiviral vector coding for a modified B-globin gene
- 6. BEST FOR You O R G A N I C S C O M P A N Y 6 As the modified B-globin gene is produced, it resulted to the production of an antisickling hemoglobin, HbAT87Q HbAT87Q is a modified adult hemoglobin with an amino acid substitution (threonine to glutamine at position 87)
- 7. BEST FOR You O R G A N I C S C O M P A N Y 7
- 8. BEST FOR You O R G A N I C S C O M P A N Y 8 TRIAL DESIGN AND OVERSIGHT • This is nonrandomized and single-dose cilinical trial conducted at 11 sites across United States in collaboration with the Bluebird Bio
- 9. BEST FOR You O R G A N I C S C O M P A N Y 9 ENTRY CRITERIA AND PATIENT POPULATION • Eligible patient were between 12 to 50 years of age, had received diagnosis of sickle cell disease • 24 month history of active treatment of sickle cell disease • No opportunity for matched HLA-identical hematopoietic-cell donation.
- 10. BEST FOR You O R G A N I C S C O M P A N Y 10 TRIAL PROCEDURES • Precollection preparation • Collection through plerixafor mobilization and apheresis • Refined LentiGlobin manufacturing process through the ex vivo transduction of HSPC with the BB305 letiviral vector
- 11. BEST FOR You O R G A N I C S C O M P A N Y 11
- 12. BEST FOR You O R G A N I C S C O M P A N Y 12
- 13. BEST FOR You O R G A N I C S C O M P A N Y 13 Conclusion Sickle cell disease is a lifelong, genetic disorder and the effect of one-time gene therapy requires a long time evaluation. It remains to be determined whether the effects of LentiGlobin gene therapy are lifelong, as anticipated on the basis of durability in clinical and precilinical studies and in studies of allogenic hematopoietic stem cell transplantation.